Banner Image
Press Image
April 16, 2021

SAN DIEGO, Calif., April 16, 2021 -- Arima Genomics, Inc., a biotechnology company focused on accelerating the adoption of spatial genomics, and SCRUM Inc., a Japanese-based distributor, combine forces to distribute genomic tools to a broader customer base.

Press Image
February 09, 2021

Epigenetics-based research tools and services company, Active Motif, Inc., announced today that it has launched an end-to-end Hi-C service in partnership with Arima Genomics, Inc. to investigate the three-dimensional folding patterns of the genome, providing researchers with greater access to this powerful technology and advancing their research.

The launch of this Hi-C service extends Active Motif’s 15 years of experience and expertise offering Epigenetic Services, such as ChIP-Seq and ATAC-Seq services, and now allows researchers to gain a deeper understanding of the biological mechanisms at play in their clinical samples or experimental systems. Active Motif continues to offer the most comprehensive offering of epigenetic services in the industry, and this new Hi-C service gives researchers even more ways to analyze their samples.

Hi-C is the predominant method used by the research community and multiple large consortia such as ENCODE and 4D Nucleome to investigate how genome folding and mis-folding impacts gene accessibility, regulation, and expression, and its impact on disease states. Active Motif has entered into an agreement with Arima Genomics, a leading company accelerating the spatial understanding of the genome, to launch their end-to-end Hi-C service as an Active Motif Epigenetic Service to serve academic, pharma, and clinical researchers.

“This is an important strategic collaboration for both organizations,” said Fritz Eibel, Chief Commercial Officer at Active Motif. “There are several commercially available Hi-C kits and our validation has shown that the Arima-HiC+ kits provide superior data resolution, ease of use, and reproducibility. These requirements are essential to study genetics and epigenetics in both the biopharma and translational medicine settings where precious patient samples are investigated.”

“We are excited that Active Motif, a thought leader and major player in the epigenetics market, compared, validated, and selected Arima versus other options,” said Siddarth Selvaraj, CEO of Arima Genomics. “We believe that the spatial genome information is an indispensable complement to the genome sequence when used for medical research, diagnosis, and therapy development. In addition to our recent selection by the Wellcome Sanger Insitute, this collaboration with Active Motif is a significant step in the company’s goal of delivering market-leading science and to democratize the access of this essential technology.”

 

About Active Motif, Inc.

Active Motif is the industry leader in developing and delivering innovative tools and custom services to enable epigenetics and gene regulation research for the life science, clinical, pharmaceutical, and drug discovery communities. The company has a world-leading portfolio of assays, reagents, and genome-wide analysis services in the field of epigenetics and gene regulation. Active Motif operates globally through its corporate headquarters in Carlsbad, California, with regional headquarters in Belgium, Japan, and China, and has a worldwide network of sales and support offices. Active Motif applies a multi-disciplinary approach to create new and modify existing technologies to meet the current and future needs of life science researchers.

About Arima Genomics, Inc.

Arima Genomics, based in San Diego, California, is a biotechnology company that aims to accelerate the understanding of spatial genomics toward discovery, diagnosis and therapy.

Press Image
October 05, 2020

SAN DIEGO--()--Arima Genomics, Inc., a biotechnology company accelerating the adoption of the genome structure information, announced today that its new high-coverage HiC technology has been evaluated and implemented at the Wellcome Sanger Institute for projects, including the Darwin Tree of Life project, in an effort to explore the true genetic diversity between species and between individuals within a species.

Press Image
March 16, 2020

SAN DIEGO--()--Arima Genomics, Inc., a biotechnology company focused on accelerating the adoption of genome structure information toward medical research, diagnosis and therapy, announced today the full commercial launch of the HiChIP application built on its existing Arima-HiC platform. With this launch, researchers can now obtain long-range chromatin interactions specifically enriched at genomic locations occupied by proteins of interest from a single experiment, enabling speed to discovery and publication with reduced costs.

Press Image
February 24, 2020

SAN DIEGO--()--Arima Genomics, Inc., a company focused on research tools to accelerate the understanding of genome sequence and structure toward their role in human health and disease, announces that it has completed its Series A round of financing. Agilent Technologies, Inc. (NYSE: A) and Cowin Venture led this round, joined by Vectr Ventures and Berkeley Catalyst Fund.

Press Image
August 28, 2019

The Genome 10K’s Vertebrate Genomes Project (VGP) and the Earth BioGenome Project (EBP) are moving ahead in their quests to sequence the genomes of all living vertebrate species and all eukaryotic species, respectively.

Press Image
April 17, 2019

Google Maps in 3D accelerates our understanding of direction and travel, likewise, ability to view genomes in 3D accelerates our understanding of the role genetics plays in human health and disease.

Press Image
March 26, 2019

Two ongoing efforts to produce new human genome assemblies are combining ultra-long nanopore reads with other types of sequencing and mapping data to generate gapless or near-gapless assemblies that can serve as reference genomes for future studies.

Press Image
January 17, 2019

Gene regulation is offering a new class of targets that operate on a higher level than DNA sequences and epigenetic markers: 3-D genomic structures. While strategies to drug the 3-D genome are still in their infancy, the growing accessibility of mapping technologies is paving the way for translation in cancer and developmental disorders.

Press Image
November 05, 2018

Arima Genomics introduces enhanced Arima-HiC product offering to drive greater insights for chromatin conformation and genome assembly studies

Press Image
September 18, 2018

The Genome 10K consortium (G10K) announces the official launch of the Vertebrate Genome Project (VGP) and its first release of 15 new, high-quality reference genomes for 14 species representing all five vertebrate classes – mammals, birds, reptiles, amphibians, and fishes. As a selected partner for the current Phase 1 of VGP, Arima Genomics delivered high quality Hi-C proximity-ligation (referred to as Arima-HiC) data necessary to achieve whole chromosome-spanning assemblies.

Press Image
January 17, 2017

Arima-HiC services is selected by the prestigious G10K consortium to generate ‘near-gapless’ reference genome assemblies for all vertebrate order species (phase 1). In a second related story, Arima Genomics today launches an early access program for its rapid, robust, and easy-to-use Arima-HiC kits to satisfy the high demand for HiC technology.